NVCR - Novocure Ltd Stock Price, Fair Value and News

22.00USD-0.17 (-0.77%)Market Closed

Market Summary

USD22.00-0.17

Market Closed

-0.77%

NVCR Alerts

Losses in recent quarter

NVCR Stock Price

View Fullscreen

NVCR RSI Chart

NVCR Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-12.28

Price/Sales (Trailing)

4.5

EV/EBITDA

-14.55

Price/Free Cashflow

-19.57

NVCR Price/Sales (Trailing)

NVCR Profitability

Operating Margin

74.82%

EBT Margin

-32.78%

Return on Equity

-53.64%

Return on Assets

-17.19%

Free Cashflow Yield

-5.11%

NVCR Fundamentals

NVCR Revenue

Revenue (TTM)

525.7M

Rev. Growth (Yr)

13.36%

Rev. Growth (Qtr)

3.53%

NVCR Earnings

Earnings (TTM)

-192.7M

Earnings Growth (Yr)

26.95%

Earnings Growth (Qtr)

17.67%

Breaking Down NVCR Revenue

Last 7 days

33.6%

Last 30 days

82.6%

Last 90 days

36.3%

Trailing 12 Months

-72.3%

How does NVCR drawdown profile look like?

NVCR Financial Health

Current Ratio

6.26

Debt/Equity

1.59

Debt/Cashflow

-0.15

NVCR Investor Care

Shares Dilution (1Y)

1.32%

Diluted EPS (TTM)

-1.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	525.7M	0	0	0
2023	522.5M	507.7M	504.0M	509.3M
2022	537.9M	545.2M	542.6M	537.8M
2021	527.2M	544.8M	545.8M	535.0M
2020	379.8M	409.0M	449.6M	494.4M
2019	269.3M	294.5M	321.8M	351.3M
2018	194.3M	217.4M	232.1M	248.1M
2017	104.7M	125.2M	153.6M	177.0M
2016	40.9M	52.3M	65.0M	82.9M
2015	19.9M	24.3M	28.7M	33.1M
2014	0	0	12.9M	15.5M
2013	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Novocure Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	leonard frank x	sold	-13,448	16.01	-840	evp, pres., novocure oncology
Mar 04, 2024	groenhuysen wilhelmus cm	sold	-19,484	16.01	-1,217	chief operating officer
Mar 01, 2024	leonard frank x	sold	-26,909	16.0269	-1,679	evp, pres., novocure oncology
Mar 01, 2024	groenhuysen wilhelmus cm	sold	-33,768	16.0269	-2,107	chief operating officer
Feb 28, 2024	leonard frank x	sold	-33,544	16.1428	-2,078	evp, pres., novocure oncology
Feb 28, 2024	groenhuysen wilhelmus cm	sold	-37,176	16.1428	-2,303	chief operating officer
Feb 27, 2024	puri michal nath	acquired	1,166,660	16.3	71,574	chief human resources officer
Feb 27, 2024	leupin nicolas	acquired	833,321	16.3	51,124	chief medical officer
Feb 27, 2024	leonard frank x	acquired	1,666,660	16.3	102,249	evp, pres., novocure oncology
Feb 27, 2024	cordova ashley	acquired	1,666,660	16.3	102,249	chief financial officer

Which funds bought or sold NVCR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	18.92	1,743,580	8,860,370	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.28	-13,521	1,593,600	-%
May 16, 2024	Colony Group, LLC	added	72.86	652,000	1,458,000	0.01%
May 16, 2024	Tidal Investments LLC	new	-	695,004	695,004	0.01%
May 15, 2024	AMUNDI	sold off	-100	-883,800	-	-%
May 15, 2024	LMR Partners LLP	new	-	240,296	240,296	-%
May 15, 2024	Palo Alto Investors LP	unchanged	-	393,336	8,782,620	0.99%
May 15, 2024	CAPITAL FUND MANAGEMENT S.A.	added	31.64	304,354	1,109,240	-%
May 15, 2024	Engineers Gate Manager LP	reduced	-15.01	-547,514	4,420,740	0.12%
May 15, 2024	PDT Partners, LLC	added	660	2,573,630	2,943,470	0.28%

Are Funds Buying or Selling NVCR?

Are funds buying NVCR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NVCR

No. of Funds

NVCR Alerts

Losses in recent quarter

Unveiling Novocure Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.13%	9,759,087	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital international investors	8.3%	8,896,076	SC 13G/A
Feb 09, 2024	capital world investors	3.1%	3,276,996	SC 13G/A
Feb 09, 2024	blackrock inc.	8.2%	8,792,035	SC 13G/A
Dec 11, 2023	capital world investors	5.5%	5,834,080	SC 13G/A
Nov 09, 2023	baillie gifford & co	4.77%	5,095,777	SC 13G/A
Feb 13, 2023	capital world investors	12.3%	12,899,395	SC 13G/A
Feb 13, 2023	capital international investors	7.8%	8,155,909	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Novocure Ltd

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Mar 27, 2024	8-K	Current Report
Mar 05, 2024	4	Insider Trading
Mar 05, 2024	4	Insider Trading
Mar 04, 2024	144	Notice of Insider Sale Intent
Mar 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Novocure Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Novocure Ltd News

Latest updates

Novocure Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	3.5%	138,503	133,784	127,321	126,051	122,182	128,429	130,998	140,866	137,547	133,213	133,606	133,517	134,695	143,953	132,660	115,925	101,828	99,234	92,062	86,713	73,309
Cost Of Revenue	3.5%	33,689	32,556	32,092	34,018	29,614	28,888	29,749	28,503	27,727	29,687	30,206	28,599	26,385	28,136	28,395	25,474	24,496	24,786	22,900	21,106	19,814
Gross Profit	3.5%	104,814	101,228	95,229	92,033	92,568	99,541	101,249	112,363	109,820	103,526	103,400	104,918	108,310	115,817	104,265	90,451	77,332	74,448	69,162	65,607	53,495
Operating Expenses	-4.3%	146,334	152,944	153,474	154,693	152,817	142,519	125,860	133,491	110,626	126,924	111,952	117,213	108,398	103,725	89,243	83,783	80,713	74,295	65,307	64,411	59,613
S&GA Expenses	-6.7%	55,206	59,188	57,964	58,488	51,169	49,629	41,395	44,750	37,884	38,982	32,580	34,138	31,357	31,359	29,364	28,461	28,834	26,804	23,830	23,708	22,333
R&D Expenses	-5.0%	51,598	54,308	53,623	55,427	59,704	54,820	51,956	57,075	42,234	56,931	48,141	50,315	45,916	44,003	32,818	29,918	25,271	23,741	18,766	19,454	17,042
EBITDA Margin	8.7%	-0.32*	-0.35*	-0.29*	-0.25*	-0.21*	-0.13*	-0.12*	-0.10*	-0.08*	-0.08*	-0.01*	0.03*	-	-	-	-	-	-	-	-	-
Interest Expenses	100.0%	2.00	-27,942	10,023	8,756	9,169	2,784	1,194	-2,228	-1,709	98.00	1.00	1.00	1.00	16.00	1,840	3,415	3,415	3,452	3,453	3,415	3,379
Income Taxes	-16.7%	7,118	8,545	1,263	3,514	1,981	4,745	3,159	652	2,132	885	2,591	1,406	1,394	3,908	1,755	2,396	-9,765	-5,852	-630	1,227	3,661
Earnings Before Taxes	17.9%	-31,642	-38,534	-48,222	-53,904	-51,080	-32,558	-23,417	-23,356	-2,515	-25,573	-10,533	-13,235	-2,734	8,825	11,039	4,051	-5,813	-1,592	1,300	-43.00	-8,489
EBT Margin	12.9%	-0.33*	-0.38*	-0.37*	-0.32*	-0.25*	-0.15*	-0.14*	-0.11*	-0.10*	-0.10*	-0.03*	0.01*	-	-	-	-	-	-	-	-	-
Net Income	17.7%	-38,760	-47,079	-49,485	-57,418	-53,061	-37,303	-26,576	-24,008	-4,647	-26,458	-13,124	-14,641	-4,128	4,917	9,284	1,655	3,952	4,260	1,930	-1,270	-12,150
Net Income Margin	9.8%	-0.37*	-0.41*	-0.39*	-0.34*	-0.27*	-0.17*	-0.15*	-0.13*	-0.11*	-0.11*	-0.05*	-0.01*	-	-	-	-	-	-	-	-	-
Free Cashflow	-102.8%	-43,358	-21,379	-26,567	-29,668	-22,815	-10,138	16,717	11,631	-8,780	130	21,103	23,554	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.2%	1,121	1,146	1,146	1,159	1,174	1,192	1,174	1,163	1,150	1,139	1,120	1,097	1,068	1,052	431	529	502	479	444	406	370
Current Assets	-3.1%	1,003	1,034	1,048	1,065	1,089	1,112	1,102	1,095	1,081	1,074	1,069	1,046	1,015	999	383	488	462	440	407	370	336
Cash Equivalents	89.9%	457	241	155	157	187	115	244	368	192	209	691	361	326	246	235	198	183	179	210	182	154
Inventory	11.1%	42.00	38.00	37.00	33.00	32.00	29.00	27.00	30.00	29.00	24.00	23.00	27.00	28.00	27.00	26.00	26.00	23.00	24.00	24.00	25.00	24.00
Net PPE	14.4%	59.00	51.00	46.00	41.00	36.00	33.00	30.00	27.00	25.00	23.00	12.00	12.00	12.00	11.00	10.00	11.00	10.00	9.00	8.00	8.00	8.00
Liabilities	-2.8%	762	784	753	743	742	750	729	721	714	729	707	700	695	575	124	261	261	262	253	247	244
Current Liabilities	-10.5%	160	179	157	150	149	159	141	135	128	143	125	116	110	114	95.00	85.00	84.00	86.00	80.00	74.00	71.00
Long Term Debt	0.1%	570	569	568	567	566	566	565	564	563	562	561	561	560	430	-	150	149	149	149	149	149
LT Debt, Non Current	-100.0%	-	569	568	567	566	566	565	564	563	562	561	561	560	430	-	150	149	149	149	149	149
Shareholder's Equity	-0.9%	359	362	394	416	432	441	445	442	436	410	413	397	372	477	307	268	242	218	190	159	126
Retained Earnings	-3.9%	-1,024	-985	-938	-888	-831	-778	-741	-714	-690	-685	-659	-646	-631	-631	-635	-645	-646	-650	-655	-657	-655
Additional Paid-In Capital	2.5%	1,388	1,353	1,334	1,307	1,266	1,222	1,189	1,158	1,128	1,100	1,074	1,045	1,006	1,111	946	917	893	871	848	818	784
Shares Outstanding	0.5%	108	107	107	107	106	105	105	105	104	103	104	103	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,415	-	-	-	2,831	-	-	-	9,486	-	-	-	2,774	-	-	-	3,943	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-116.9%	-31,574	-14,558	-19,314	-22,737	-16,727	-3,707	22,420	15,762	-3,687	14,404	24,400	26,172	17,780	53,481	30,969	12,741	1,957	6,962	14,907	9,066	-4,315
Share Based Compensation	95.5%	34,084	17,438	26,346	32,740	39,084	29,782	26,305	25,823	25,045	22,398	25,758	27,881	18,863	20,273	20,121	18,770	16,557	14,697	14,338	13,732	9,649
Cashflow From Investing	150.0%	246,216	98,500	17,258	-13,897	82,287	-128,060	-150,244	155,757	-17,410	-499,090	302,703	-2,618	54,171	-613,638	147,218	-3,315	-3,112	-46,756	-2,174	-1,748	-989
Cashflow From Financing	-88.8%	213	1,910	1,171	7,502	5,204	3,410	4,204	4,736	3,141	3,652	3,036	11,059	7,955	570,854	-140,493	5,345	4,503	8,586	15,468	20,657	16,970

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NVCR Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Income Statement [Abstract]
Net revenues	$ 138,503	$ 122,182	$ 509,338
Cost of revenues	33,689	29,614	128,280
Gross profit	104,814	92,568	381,058
Operating costs and expenses:
Research, development and clinical studies	51,598	59,704	223,062
Sales and marketing	55,206	51,169	226,809
General and administrative	39,530	41,944	164,057
Total operating costs and expenses	146,334	152,817	613,928
Operating income (loss)	(41,520)	(60,249)	(232,870)
Financial income (expenses), net	9,878	9,169	41,130
Income (loss) before income tax	(31,642)	(51,080)	(191,740)
Income tax	7,118	1,981	15,303
Net income (loss)	$ (38,760)	$ (53,061)	$ (207,043)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.36)	$ (0.50)	$ (1.95)
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.36)	$ (0.50)	$ (1.95)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	107,266,198	105,667,072	106,391,178
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	107,266,198	105,667,072	106,391,178

NVCR Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 453,763	$ 240,821
Short-term investments	416,384	669,795
Restricted cash	3,600	1,743
Trade receivables, net	65,091	61,221
Receivables and prepaid expenses	21,479	22,677
Inventories	42,391	38,152
Total current assets	1,002,708	1,034,409
LONG-TERM ASSETS:
Property and equipment, net	58,917	51,479
Field equipment, net	11,911	11,384
Right-of-use assets	32,994	34,835
Other long-term assets	14,899	14,022
Total long-term assets	118,721	111,720
TOTAL ASSETS	1,121,429	1,146,129
CURRENT LIABILITIES:
Trade payables	84,316	94,391
Other payables, lease liabilities and accrued expenses	75,914	84,724
Total current liabilities	160,230	179,115
LONG-TERM LIABILITIES:
Long-term debt, net	569,652	568,822
Long-term leases	25,608	27,420
Employee benefit liabilities	6,566	8,258
Other long-term liabilities	18	18
Total long-term liabilities	601,844	604,518
TOTAL LIABILITIES	762,074	783,633
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 107,603,774 shares and 107,075,754 shares at March 31, 2024 (unaudited) and December 31, 2023, respectively	0	0
Additional paid-in capital	1,387,765	1,353,468
Accumulated other comprehensive income (loss)	(4,147)	(5,469)
Retained earnings (accumulated deficit)	(1,024,263)	(985,503)
TOTAL SHAREHOLDERS' EQUITY	359,355	362,496
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 1,121,429	$ 1,146,129

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

CEO	Mr. Asaf Danziger
WEBSITE	novocure.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1320

Novocure Ltd Frequently Asked Questions

What is the ticker symbol for Novocure Ltd? What does NVCR stand for in stocks?

NVCR is the stock ticker symbol of Novocure Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novocure Ltd (NVCR)?

As of Fri May 17 2024, market cap of Novocure Ltd is 2.37 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers.

What is the fair value of NVCR stock?

You can check NVCR's fair value in chart for subscribers. The fair value of Novocure Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Novocure Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NVCR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Novocure Ltd a good stock to buy?

The fair value guage provides a quick view whether NVCR is over valued or under valued. Whether Novocure Ltd is cheap or expensive depends on the assumptions which impact Novocure Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVCR.

What is Novocure Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NVCR's PE ratio (Price to Earnings) is -12.28 and Price to Sales (PS) ratio is 4.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVCR PE ratio will change depending on the future growth rate expectations of investors.